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Objective: To survey the frequency of blaTEM, blaSHV and blaCTX-M genotypes in
extended-spectrum b-lactamase (ESBL)-producing Escherichia coli (E. coli) isolated
from hospitalized patients with urinary tract infection and the determination of their
antibiotic resistance patterns.
Methods: During 11-month study, 100 ESBL-producing E. coli were collected from 330
patients who met the deﬁnition of urinary tract infection. The phenotypic identiﬁcation of
ESBL was conﬁrmed by double disk synergy test and combined disk diffusion test.
In vitro, susceptibility to ESBL isolates than 14 antimicrobial agents was performed by
Kirby-Bauer disk diffusion method. The frequency of blaTEM, blaSHV and blaCTX-M
ESBL-producing E. coli was assessed by PCR method.
Results: The frequency of ESBL-producing E. coli was 40.8%. In vitro, susceptibility to
ESBL-producing E. coli showed that the majority of isolates were highly susceptible to
amikacin (74%) and imipenem (91%). The rates of resistance to other antibiotics varied
from 33% to 96%. Through 100 tested isolates, the prevalence of blaTEM, blaSHV and
blaCTX-M genes was determined to be 67%, 45% and 74% respectively. In comparison
with other bla genes, the frequency of blaCTX-M was strikingly high.
Conclusions: Due to the increase of E. coli with multiple ESBL genes, continuous sur-
veillance in order to use appropriate antibiotics and the control of infections is necessary.1. Introduction
Urinary tract infection (UTI) is one of the most frequent
types of infections that probably affects one-half of all people
during their lifetimes. The extensive consume of b-lactam
antimicrobial agents in order to treat patients with UTI has
recently led to the emergence of resistant strains all over the
world. Beta-lactam resistance is mediated by extended-
spectrum b-lactamase (ESBL) genes that are mostly encoded
by plasmid[1]. ESBLs, a heterogeneous group of enzymes, are
encoded by genes which have been described that conferresistance to third and fourth generation cephalosporins and
monobactams but are inhibited by b-lactamase inhibitors[2].
ESBLs are grouped into four classes A, B, C and D
enzymes. Cefotaximase (CTX-M), temoneira (TEM) and
sulfhydryl variable (SHV) are class A ESBLs[3]. Escherichia
coli (E. coli) is a major agent of UTI and also the most
frequent bacteria that produces different type of ESBLs[1,2].
Several investigators have reported different prevalence of
ESBLs between 6% and 88% in various health care settings
especially among Klebsiella pneumoniae (K. pneumoniae)
and E. coli[3], but unfortunately in recent years, the
prevalence of ESBL-producing E. coli and their resistance is
increasing. More than 400 ESBLs have been described so far,
that typically, are derived by point mutation from the TEM,
SHV and CTX-M groups, with 183, 134 and 103 variants,
respectively[4].
Although, until recently, TEM and SHV variants were the
most ESBLs produced by Klebsiella spp., Enterobacter spp.,
and E. coli, the nature of ESBL dissemination has changed
during the past few years and E. coli strains expressing CTX-M
have presently replaced TEM and SHV as the most commonr the CC BY-NC-ND license
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resistance to ceftazidime, but not to cefotaxime and cefazolin,
while CTX-M b-lactamases are more active against cefotaxime
and ceftriaxone than ceftazidime[3]. At ﬁrst, the CTX-M family
was described in 1992[6]. It has only 40% similarity to TEM and
SHV[3]. Based on amino acid similarities, ﬁve different groups of
CTX-M types (1, 2, 8, 9, and 25) are known. The prevalence of
speciﬁc CTX-M subgroups varies due to geographic region and
studied country. In particular, CTX-M-15 is the most widely
disseminated CTX-M genotypes currently[4]. As mentioned, in
recent years, according to the widespread of CTX-M-type
enzyme, the epidemiology of ESBLs has dramatically
increased since 1995 in the most parts of world[1,4]. Given the
increasing prevalence of TEM, SHV and CTX-M type of
ESBLs, there is a serious threat to the clinical use of third
generation cephalosporins for the treatment of severe infections
and also limit the choice of effective antimicrobial drugs to
carbapenems or colistin[7].
The emergence of ESBLs, as an important cause of trans-
ferable multidrug resistance in Gram-negative bacteria particu-
larly E. coli, is now a serious problem in the public health world.
However, there are still few reports on the prevalence of noso-
comial ESBL-producing E. coli in hospitals of Iran. With this
background, we investigated the ESBL type prevalent of E. coli
isolated from hospitalized patients with UTI and then determi-
nated their pattern of antimicrobial resistance as commonly
antimicrobial agents consume.
2. Materials and methods
2.1. Study setting and bacterial isolates
The present descriptive study was performed on hospitalized
patients with UTI. A total of 245 E. coli isolates were collected
from the 330urine specimens ofUTI hospitalized patients during a
period of 11-month from August 2014 to June 2015. Urine sam-
ples were obtained by a wide mouth sterile container from the
study subjects. UTI was deﬁned as > 104 leukocytes per milliliter
urine and the growth of a single pathogen of > 105 CFU/mL from
urine specimens. All of patients were instructed for proper and
correct urine specimen collection. All of included cases had his-
tory of nosocomial UTI. Hospital acquired infection was
conﬁrmed by clinical examination of physicians. All the urine
samples were transported to the laboratory and processed imme-
diately. Identiﬁcation was done based on culture characteristics,
Gram stain and routine standard biochemical tests. Colony count
semi-quantitative method was done according to surface streak
procedure using calibrated loops. The cultured plates were incu-
bated in aerobic conditions at 37 C for 24–48 h. The result of
equal or more than 105 CFU/mLwas considered as a positive UTI
and a less than 102 CFU/mL was interpreted as a negative UTI.
The result of 102–104 CFU/mL was repeated[8]. Repeated E. coli
isolates were excluded from the study.
2.2. Phenotypic test for ESBL detection
ESBL production was conﬁrmed phenotypically by double
disk synergy test (DDST) and combined disk diffusion test ac-
cording to the Clinical and Laboratory Standards Institute
(CLSI) criteria for ESBL screening[9].2.3. DDST
DDST was done by using cefotaxime (30 mg) and ceftazi-
dime (30 mg) with and without clavulanic acid (10 mg) disks on
Mueller-Hinton agar (Oxoid, Basingstock, UK) with 25 mm
apart from each other. An increase of equal or more than 5 mm
in zone diameter for either antimicrobial agent tested with
clavulanic acid versus its zone when tested without clavulanic
acid indicated the presence of ESBL[10].
2.4. Combined disk diffusion method
According to the CLSI protocol, test was done by using both
ceftazidime (30 mg) disk alone and the combination of clav-
ulanic acid (30 mg/10 mg). Disks were placed 25 mm apart from
each other on Mueller-Hinton agar inoculated with 0.5 McFar-
land suspension of the test isolate. More than or equal to 5 mm
increase in zone diameter for either antimicrobial agent tested
with the combination of clavulanic acid versus its zone when
tested alone was interpreted as ESBL producer[11]. E. coli ATCC
25922 was used as quality control.
2.5. Antimicrobial susceptibility testing
Isolates were tested to evaluate the pattern of antimicrobial
susceptibilities by Kirby-Bauer disk diffusion method according
to interpretive criteria that have been recommended by CLSI
guidelines. The following antimicrobial agents were used in this
study: aztreonam (30 mg), gentamicin (10 mg), ciproﬂoxacin
(5 mg), amikacin (30 mg), ceftazidime (30 mg), imipenem
(10 mg), cefotaxime (30 mg), piperacillin (100 mg), cefoxitin
(30 mg), cephalexin (30 mg), co-trimoxazole (25 mg), amoxicillin
(30 mg), penicillin (10 mg), nalidixic acid (30 mg). In this
research, antibiotic disks were supplied by HiMedia Labora-
tories Pvt. Ltd., Mumbai, India. Brieﬂy, after preparation of
bacterial suspension, the turbidity of each of them was adjusted
equivalent to a No. 0.5 McFarland standard and then inoculated
on Mueller-Hinton agar. After overnight incubation at 37 C,
diameters of inhibition zones were read and the results were
interpreted as susceptible, intermediate, and resistant. The
conﬁrmed samples as E. coli were stored in tryptic soy broth
(Merck, Germany) containing 20% glycerol at −70 C and were
subjected to further molecular identiﬁcation.
2.6. DNA extraction and PCR of blaTEM, blaSHV and
blaCTX-M genes
DNA was extracted from pure colony of an overnight growth
of E. coli isolates on Luria-Bertani agar (Oxoid, UK) by using
QIAamp DNA isolation columns (Qiagen, Hilden, Germany)
according to the manufacturer's procedure. The concentration of
extracted DNA was assessed by spectrophotometer. E. coli
isolates that included in the study were screened by PCR method
and using speciﬁc oligonucleotide primers to determine blaTEM,
blaSHV and blaCTX-M genes. Primer sequences and their size
were used for the detection of blaTEM, blaSHV and blaCTX-M
genes in this study, which are listed in Table 1.
The PCR reactions for detection of blaTEM, blaSHV and
blaCTX-M genes were done in a total volume of 25 mL by using
Master Mix Red, Taq DNA polymerase with MgCl2, amplicon.
Table 1
Oligonucleotide primers were used for the detection of bla genes.
Gene Nucleotide sequence Fragment
length
(bp)
Reference
blaTEM 5-TCGGGGAAATGTGCGCG-30 972 [12]
5-TGCTTAATCAGTGAGGCAC
C-30
blaSHV 5-GGGTTATTCTTATTTGTCG
C-30
615 [10]
5-TTAGCGTTGCCAGTGCTC-30
blaCTX-M 5-ACGCTGTTGTTAGGAAGT
G-30
857 [10]
5-TTGAGGCTGGGTGAAGT-30
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blaSHV and blaCTX-M genes are presented in Table 2.Table 2
PRC programs used in this study.
Gene Program Number of cycles
blaTEM 5 min 94 C initial denaturation 35
45 s 94 C denaturation
30 s 54 C annealing
1 min 72 C extension
5 min 72 C ﬁnal extension
blaSHV 5 min 94 C initial denaturation 30
45 s 94 C denaturation
1 min 56 C annealing
1 min 72 C extension
5 min 72 C ﬁnal extension
blaCTX-M 3 min 94 C initial denaturation 36
1 min 94 C denaturation
30 s 58 C annealing
1 min 72 C extension
10 min 72 C ﬁnal extension
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Figure 1. The susceptibly pattern of 100 ESBL-producing E. coli isolates
to 14 antimicrobial agents.
A: Amoxicillin; B: Penicillin; C: Co-trimoxazole; D: Ceftazidime; E:
Cefotaxime; F: Cefoxitin; G: Ciproﬂoxacin; H: Gentamicin; I: Cephalexin;
J: Nalidixic acid; K: Piperacillin; L: Aztreonam; M: Amikacin; N:
Imipenem.
Figure 2. Detection of gene encoding blaCTX-M in ESBL-producing E. coli
by PCR.
Lane M: Ladder (Fermentas, UK); Lanes 1–4: The 857 bp PCR product of
blaCTX-M; Lane 5: Positive control (K. pneumoniae ATCC 700603); Lane
6: Negative control (E. coli ATCC 25922).The amplicons were separated by 1.2% agarose gel electro-
phoresis at 80 V for 2 h. After electrophoresis, fragments were
stained by ethidium bromide and visualized by using ultraviolet
light. PCR products were sequenced. Then, nucleotide sequences
were compared with sequences in the GenBank and European
Molecular Biology Laboratory databases by using the BLAST.
2.7. Statistical analysis
The results were analyzed by using SPSS version 17.0 (SPSS
Inc., Chicago, USA).
3. Results
In this study, from 330 urine specimens of hospitalized pa-
tients with UTI, 245 (74.2%) E. coli isolates were collected and
100 (40.8%) isolates of them were ESBL producer and recruited
for the study. The mean age was 45 years old and the range of
patient's age was from 11 months to 75 years old. There were 71
(71%) females and 29 (29%) males and the male: female ratio
was 0.41. The occurrence of UTI was high in the age's group
36–60 years (59%) and also, between the age of 20 and 35 years
(4%) was low and equal. A total of 25 (25%) patients had a
history of UTI, and 32 (32%) patients had taken antimicrobial
therapy. Over 63% of them had been treated with the b-lactam
antibiotics. In this research, the same number of ESBL positiveisolates were detected by both phenotypic methods of DDST and
disk diffusion test.
The result of disk diffusion susceptibility testing of clinical
samples revealed that all of the E. coli producing ESBLs were
resistant to amoxicillin and penicillin. The susceptibility rates of
isolates to other antibiotics were: co-trimoxazole 96%; ceftazi-
dime 82%; cefotaxime 78%; cefoxitin 71%; ciproﬂoxacin 69%;
gentamicin 65%; cephalexin 63%; nalidixic acid 61%; piper-
acillin 39%; aztreonam 33%. Most of isolates were highly sus-
ceptible to amikacin 74% and imipenem 91%. The results also
showed that none of isolates were sensitive to all antibiotics.
In vitro, the susceptibility of ESBL-producing strains to 14 an-
tibiotics are shown in Figure 1.
Isolates resistant to at least three or more unrelated antibiotics
were determined via multidrug-resistant[13]. All of isolates
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multidrug-resistant to 3, 4, 5, 6 and more antibiotics were 7
(7%), 10 (10%), 8 (8%), 11 (11%) and 64 (64%).
The predominant resistant proﬁle among our isolates con-
sisted of 10 antibiotics amoxicillin, penicillin, co-trimoxazole,
ceftazidime, cefotaxime, cefoxitin, ciproﬂoxacin, cephalexin,
nalidixic acid and aztreonam (13%), followed by resistance to 8
antibiotics amoxicillin, penicillin, co-trimoxazole, ceftazidime,
cefotaxime, cefoxitin, cephalexin and aztreonam (11%).
The PCR data of ESBL-producing strains revealed that
blaCTX-M genes were the most frequent ESBL types (74%), fol-
lowed by blaTEM (67%) and ﬁnally blaSHV (45%) respectively
(Figures 2–4). Forty ﬁve (45%) out of 100 isolates carried more
than one type of b-lactamase genes. Co-existence of the blaCTX-M
and blaTEM was detected in 22 isolates (22%), blaCTX-M andFigure 3. Detection of gene encoding blaTEM in ESBL-producing E. coli
by PCR.
Lane M: Ladder (Fermentas, UK); Lane 1: Negative control (E. coli ATCC
25922); Lanes 2 and 3: The 972 bp PCR product of blaTEM; Lane 4:
Positive control (K. pneumoniae ATCC 700603).
Figure 4. Detection of gene encoding blaSHV in ESBL-producing E. coli
by PCR.
Lane M: Ladder (Fermentas, UK); Lanes 1–3: The 615 bp PCR product of
blaSHV; Lane 4: Positive control (K. pneumoniae ATCC 700603); Lane 5:
Negative control (E. coli ATCC 25922).blaSHV in 12 isolates (12%), blaTEM and blaSHV in 8 isolates
(8%) and blaCTX-M, blaSHV and blaTEM in 3 isolates (3%). Fifty
ﬁve isolates (55%) carried only one of ESBL genes.
4. Discussion
The increase of resistance to antibiotics and the existence of
multidrug-resistant in ESBL producers have become an
emerging public health problem due to the clinical failure of
empirical treatment protocols[14]. Although the mechanism of
resistance among ESBL-producing E. coli may be varied, it
has been documented that the most common mechanism of
resistance to b-lactam antibiotics in E. coli isolates is b-lacta-
mase production.
The present study was conducted on 100 ESBL-producing
E. coli isolates. The results exhibited that all of isolates were
resistant to amoxicillin and penicillin and none of them were
sensitive to all tested antibiotics. The lowest rates of resistance in
ESBL-producing isolates were observed for imipenem 8% and
amikacin 18%. This is an alarm for clinicians that the con-
sumption and prescription of these antibiotics must be changed.
Our ﬁnding is in accordance with recent data[15].
In a study, there were 100 specimens of E. coli isolated
from the urine samples and their resistance to antibiotics
penicillin, amoxicillin, cephalexin, ceftriaxone and imipenem
was 100%, 100%, 43%, 46% and 2% respectively[15]. These
results exhibited a high frequency of resistance among
E. coli isolates to the common antibiotics especially
penicillin, amoxicillin and cephalosporins such as cefotaxime
and ceftazidime which are used routinely in the treatment of
UTIs. According to another study that was conducted by the
European Antibiotic Resistance Surveillance System in 2006,
continuous increase of resistant to third generation
cephalosporins has been reported in over 800 laboratories
from 31 countries[16]. Overall, due to indiscriminate use of
antibiotics and low standard of personal and community
hygiene, the percentage of E. coli resistance to
chloramphenicol, ampicillin, tetracycline, aminoglycosides
and sulphonamides in developing countries is higher than
industrialized countries[17].
In our study, the most age group infected with ESBL-
producing E. coli was 36–60 years (59%). Our ﬁnding,
regarding the age of the patients, is in accordance with recent
data that state aging is a risk factor for b-lactamase-mediated
resistance in patients infected with enterobacteria.
In recent years, ESBL-producing E. coli isolates have been
increased frequently from different parts of the world particularly
Asia[18]. In our study, the ESBL-producing E. coli isolates were
40.8% of all E. coli collected over a period of 11 months. The
prevalence of ESBL-producing strains varies due to geographic
region, studied country and institution. In this respect, several
studies expressed that the ESBL production is much less frequent
in Europe than in Latin America and Asia, and they are even less
frequent in the Paciﬁc than in North America[19].
The frequency of ESBL-producing E. coli was 40.8% in our
study, which was lower than that in Turkey (84%)[7], Portugal
(67.9%)[2], India (66.7%)[20], United Arab Emirates (41%)[21],
but was higher than those in Japan (20.4%)[22], Kuwait
(31.7%)[23], Saudi Arabia (30.6%)[24], Thailand (13.2%)[25], and
Colombia (11.7%)[26]. This may be due to the differences in
the type of samples, in the time of sample's collection,
consumption of antibiotics and differences.
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producing isolates is usually common due to carrying multi-
resistant genes and plasmids[2,5,6,10,27]. In the present study, our
isolates were resistant not only to b-lactam but also to
different antibiotic families including trimethoprim/
sulfamethoxazole, ﬂuoroquinolones and aminoglycosides. This
obtained resistance pattern was similar to those commonly
described in other studies[17,27].
As previous noted, the most prevalent types of ESBLs are
SHV-, TEM- and CTX-M-type that arise mainly due to mu-
tations in b-lactamase genes. We detected a variety of b-lac-
tamases among the E. coli isolates namely, SHV, TEM and
CTX-M. Although TEM and SHV variants were the most
common ESBLs during the past decade, newly CTX-M b-
lactamases have emerged as prevalent ESBL worldwide type
compared to the TEM and SHV genotypes[4]. Regarding the
different types of ESBLs, as expected, CTX-M enzymes
were the most common ESBL types (74%) followed by TEM
(67%) and SHV (45%). The high prevalence of CTX-M gene
in our study, we are in agreement with some earlier reports. In
2007, Seputien _e et al. showed the high prevalence of CTX-M
among E. coli (96%) and K. pneumoniae (71%) isolates,
showing the ESBL phenotype[28]. In a study which was done
on 181 unduplicated E. coli strains isolated in nine different
hospitals in three Portuguese regions in 2007, it showed that
CTX-M producer strains were prevalent among UTIs
(76%)[29]. Another study that was conducted in Turkey (2013)
showed that CTX-M was the most prevalent b-lactamase
among ESBL-producing E. coli isolates (83.18%)[30]. On the
basis of our results, it can be argued that current ESBL
epidemiology in our study is consistent with some
neighboring countries and Europe[23,24,29]. These higher rates
of CTX-M among our isolates may be associated with high
mobilization of the encoding genes. Barlow et al. reported
increased tenfold in movement of blaCTX-M genes via
plasmid in compare to other class A b-lactamases[31]. Our
ﬁndings about CTX-M conﬁrm the theory that CTX-M en-
zymes are replacing SHV and TEM enzymes as the prevalent
ESBL type.
In several studies, the predominant genotypes of ESBLs were
diverse. In studies performed in Italia (45.4%)[32], Portugal
(40.9%)[2], and Turkey (72.7%)[7], the most predominant ESBL
genotype was TEM.
Our survey demonstrated a relatively high prevalence of
SHV gene (45%), which was lower than Sweden (63%)[33], and
India (57.5%)[34], but was higher than those in Thailand
(3.8%)[25], Saudi Arabia (23.1%)[24], and Turkey (9.09%)[7].
The co-existence of different b-lactamases genes within the
same isolates has been reported by several investigators[5]. Our
ﬁndings showed that about one-half of the ESBL-producing
E. coli isolates were molecularly conﬁrmed to have two or
more ESBL genes. The most common ESBL genotype among
our isolates was CTX-M and TEM (22%). This result is in
agreement with ﬁndings of Harada et al. in Japan[22], Sharma
et al. in India[34], and Hassan et al.[24], in Saudi Arabian who
reported TEM + CTX-M as the most common type.
Our study suggests that E. coli strains carrying multiple
ESBL genes are widespread in Iran. CTX-M-producing E. coli
strains are currently a problem in Iran which may be related to
the misuse of third generation cephalosporins, especially
cefotaxime. Therefore, isolation and detection of ESBL-
producing strains are essential for the selection of the mosteffective antibiotic for treatment and also infection control.
Overall, continuous monitoring and effective infection control
measures, rational use of drugs and also the use of carbape-
nems instead of extended-spectrum cephalosporins, quino-
lones, and aminoglycosides for treating infections in which
ESBL-producing strains are likely to emerge could be
effective.
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